InvestorsHub Logo
Followers 241
Posts 28600
Boards Moderated 0
Alias Born 07/08/2009

Re: pire post# 318

Thursday, 08/12/2010 11:16:27 AM

Thursday, August 12, 2010 11:16:27 AM

Post# of 38310
Called and briefly talked to the IR(Dan Myers) today and chatted a little about the stock, he did not tell me anything that was encouraging in short term but did comment about certain issues that are still in the works. Things such as the intentional agreement with Genesis Biopharma, Inc to acquire an exclusive worldwide sublicense to further develop a new pharmaceutical to treat diabetic neuropathy.

I am letting you all know that I did get an answer with a real person on the other end of the line and not a leave a message bullshiet that does not get returned.

Latest PR on negotiation with Genesis Biopharma released on July 19, 2010:

TRDX Announces Negotiations Progressing Well With Genesis Biopharma; Definitive Agreement and Closing Expected Shortly
TREND EXPLORATION INC (OTC) (USOTC:TRDX)
Historical Stock Chart
1 Month : July 2010 to August 2010

SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today announces to its shareholders that its negotiations are progressing well towards a definitive agreement with Genesis Biopharma, Inc. ("Genesis") to acquire an exclusive worldwide sublicense for a new compound in development for the treatment of Painful Diabetic Neuropathy (PDN).

The Company expects the definitive agreement and subsequent closing to be finalized in a reasonably short period of time.

Dr. Jan Stahl, CEO of TRDX, commented: "We are pleased to be nearing completion of negotiations with Genesis. Additionally, plans for funding the development of Genesis' PDN solution are progressing. We look forward to the successful completion of these key milestones in the near future."



testing 1 2 3